Advances in new antivirals for chronic hepatitis B.
10.1097/CM9.0000000000001994
- Author:
Yanhua TANG
1
;
Hongyan LIANG
;
Ge ZENG
;
Sheng SHEN
;
Jian SUN
Author Information
1. State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
- Publication Type:Review
- MeSH:
Antiviral Agents/therapeutic use*;
Hepatitis B/drug therapy*;
Hepatitis B Surface Antigens;
Hepatitis B virus;
Hepatitis B, Chronic/drug therapy*;
Hepatitis C, Chronic/drug therapy*;
Humans
- From:
Chinese Medical Journal
2022;135(5):571-583
- CountryChina
- Language:English
-
Abstract:
Chronic hepatitis B virus (HBV) infection remains a global health burden. Timely and effective antiviral therapy is beneficial for patients with HBV infection. With existing antiviral drugs, including nucleos(t)ide analogs and interferon-alfa, patients can achieve viral suppression with improved prognosis. However, the rate of hepatitis B surface antigen loss is low. To achieve a functional cure and even complete cure in chronic hepatitis B patients, new antivirals need to be developed. In this review, we summarized the advantages and disadvantages of existing antiviral drugs and focused on new antivirals including direct-acting antiviral drugs and immunotherapeutic approaches.
